Kalaris Therapeutics (KLRS) Short Interest Ratio & Short Volume $6.64 -0.45 (-6.35%) As of 04:00 PM Eastern Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsOwnershipSEC FilingsShort InterestTrendsBuy This Stock Kalaris Therapeutics Short Interest DataKalaris Therapeutics (KLRS) has a short interest of 516,700 shares, representing 10.01% of the float (the number of shares available for trading by the public). This marks a 176.31% increase in short interest from the previous month. The short interest ratio (days to cover) is 1.9, indicating that it would take 1.9 days of the average trading volume of 123,997 shares to cover all short positions.Current Short Interest516,700 sharesPrevious Short Interest187,000 sharesChange Vs. Previous Month+176.31%Dollar Volume Sold Short$1.92 millionShort Interest Ratio1.9 Days to CoverLast Record DateSeptember 15, 2025Outstanding Shares18,700,000 sharesFloat Size5,160,000 sharesShort Percent of Float10.01%Today's Trading Volume111,743 sharesAverage Trading Volume123,997 sharesToday's Volume Vs. Average90% Short Selling Kalaris Therapeutics? Sign up to receive the latest short interest report for Kalaris Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartKLRS Short Interest Over TimeKLRS Days to Cover Over TimeKLRS Percentage of Float Shorted Over Time Kalaris Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 9/15/2025516,700 shares $1.92 million +176.3%10.0%1.9 $3.71 8/31/2025187,000 shares $762.96 thousand No Change3.6%0.8 $4.08 KLRS Short Interest - Frequently Asked Questions What is Kalaris Therapeutics' current short interest? Short interest is the volume of Kalaris Therapeutics shares that have been sold short but have not yet been closed out or covered. As of September 15th, traders have sold 516,700 shares of KLRS short. 10.01% of Kalaris Therapeutics' shares are currently sold short. Learn More on Kalaris Therapeutics' current short interest. What is a good short interest ratio for Kalaris Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. KLRS shares currently have a short interest ratio of 2.0. Learn More on Kalaris Therapeutics's short interest ratio. What is a good short interest percentage for Kalaris Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 10.01% of Kalaris Therapeutics' floating shares are currently sold short. Is Kalaris Therapeutics' short interest increasing or decreasing? Kalaris Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 516,700 shares, an increase of 176.3% from the previous total of 187,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Kalaris Therapeutics' float size? Kalaris Therapeutics currently has issued a total of 18,700,000 shares. Some of Kalaris Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Kalaris Therapeutics currently has a public float of 5,160,000 shares. How does Kalaris Therapeutics' short interest compare to its competitors? 10.01% of Kalaris Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Kalaris Therapeutics: Korro Bio, Inc. (28.08%), Altimmune, Inc. (28.42%), Rocket Pharmaceuticals, Inc. (13.80%), Canopy Growth Corporation (6.97%), Rapt Therapeutics (5.85%), CytomX Therapeutics, Inc. (17.56%), Amarin Corporation PLC (1.96%), Annexon, Inc. (8.71%), I-Mab Sponsored ADR (3.44%), 4D Molecular Therapeutics, Inc. (10.04%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Corporation ($8.81 billion), Canadian Natural Resources Limited ($5.82 billion), Reddit Inc. ($5.19 billion), Coinbase Global, Inc. ($4.52 billion), Robinhood Markets, Inc. ($4.30 billion), Charter Communications, Inc. ($3.75 billion), CoreWeave Inc. ($3.66 billion), Seagate Technology Holdings PLC ($3.57 billion), Live Nation Entertainment, Inc. ($3.33 billion), and Rocket Lab Corporation ($3.26 billion). View all of the most shorted stocks. What does it mean to sell short Kalaris Therapeutics stock? Short selling KLRS is an investing strategy that aims to generate trading profit from Kalaris Therapeutics as its price is falling. KLRS shares are trading down $0.23 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Kalaris Therapeutics? A short squeeze for Kalaris Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of KLRS, which in turn drives the price of the stock up even further. How often is Kalaris Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KLRS, twice per month. The most recent reporting period available is September, 15 2025. More Short Interest Resources from MarketBeat Related Companies Autolus Therapeutics Short Interest Data Astria Therapeutics Short Interest Data ADC Therapeutics Short Interest Data PureTech Health Short Interest Data 4D Molecular Therapeutics Short Interest Data Y-mAbs Therapeutics Short Interest Data Evolus Short Interest Data Kamada Short Interest Data Aura Biosciences Short Interest Data Korro Bio Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:KLRS) was last updated on 10/3/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kalaris Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kalaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.